130 related articles for article (PubMed ID: 35037102)
21. Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients.
De Santis MC; La Rocca E; Meneghini E; Bregni G; Di Lorenzo G; Galli G; Di Nicola M; Folli S; Gennaro M; Pruneri G; Paolini B; Daidone MG; De Braud F; Apolone G; Sant M; Di Cosimo S
Clin Transl Oncol; 2020 May; 22(5):786-792. PubMed ID: 31372896
[TBL] [Abstract][Full Text] [Related]
22. Association of the Interaction Between Mammographic Breast Density, Body Mass Index, and Menopausal Status With Breast Cancer Risk Among Korean Women.
Tran TXM; Moon SG; Kim S; Park B
JAMA Netw Open; 2021 Dec; 4(12):e2139161. PubMed ID: 34940866
[TBL] [Abstract][Full Text] [Related]
23. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
24. The relationship between terminal duct lobular unit features and mammographic density among Chinese breast cancer patients.
Sung H; Guo C; Li E; Li J; Pfeiffer RM; Guida JL; Cora R; Hu N; Deng J; Figueroa JD; Sherman ME; Gierach GL; Lu N; Yang XR
Int J Cancer; 2019 Jul; 145(1):70-77. PubMed ID: 30561789
[TBL] [Abstract][Full Text] [Related]
25. Defining radiologic complete response using a correlation of presurgical ultrasound and mammographic localization findings with pathological complete response following neoadjuvant chemotherapy in breast cancer.
Makanjuola DI; Alkushi A; Al Anazi K
Eur J Radiol; 2020 Sep; 130():109146. PubMed ID: 32673929
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer risk factors and mammographic density among 12518 average-risk women in rural China.
Yan H; Ren W; Jia M; Xue P; Li Z; Zhang S; He L; Qiao Y
BMC Cancer; 2023 Oct; 23(1):952. PubMed ID: 37814233
[TBL] [Abstract][Full Text] [Related]
27. The Association of Mammographic Density and Molecular Breast Cancer Subtype.
Edwards BL; Atkins KA; Stukenborg GJ; Novicoff WM; Larson KN; Cohn WF; Harvey JA; Schroen AT
Cancer Epidemiol Biomarkers Prev; 2017 Oct; 26(10):1487-1492. PubMed ID: 28698184
[No Abstract] [Full Text] [Related]
28. Association between mammographic density and tumor marker-defined breast cancer subtypes: a case-control study.
Shin J; Lee JE; Ko HY; Nguyen TL; Nam SJ; Hopper JL; Song YM
Eur J Cancer Prev; 2018 May; 27(3):239-247. PubMed ID: 28957821
[TBL] [Abstract][Full Text] [Related]
29. Risk stratification of women with false-positive test results in mammography screening based on mammographic morphology and density: A case control study.
Winkel RR; Euler-Chelpin MV; Lynge E; Diao P; Lillholm M; Kallenberg M; Forman JL; Nielsen MB; Uldall WY; Nielsen M; Vejborg I
Cancer Epidemiol; 2017 Aug; 49():53-60. PubMed ID: 28558329
[TBL] [Abstract][Full Text] [Related]
30. Mammographic breast density is associated with the development of contralateral breast cancer.
Raghavendra A; Sinha AK; Le-Petross HT; Garg N; Hsu L; Patangan M; Bevers TB; Shen Y; Banu A; Tripathy D; Bedrosian I; Barcenas CH
Cancer; 2017 Jun; 123(11):1935-1940. PubMed ID: 28135395
[TBL] [Abstract][Full Text] [Related]
31. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
32. Mammographic breast density and breast cancer risk in a Mediterranean population: a nested case-control study in the EPIC Florence cohort.
Masala G; Ambrogetti D; Assedi M; Bendinelli B; Caini S; Palli D
Breast Cancer Res Treat; 2017 Jul; 164(2):467-473. PubMed ID: 28478611
[TBL] [Abstract][Full Text] [Related]
33. Inter-observer agreement according to three methods of evaluating mammographic density and parenchymal pattern in a case control study: impact on relative risk of breast cancer.
Winkel RR; von Euler-Chelpin M; Nielsen M; Diao P; Nielsen MB; Uldall WY; Vejborg I
BMC Cancer; 2015 Apr; 15():274. PubMed ID: 25884160
[TBL] [Abstract][Full Text] [Related]
34. BMI and Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Study and Meta-Analysis.
Erbes T; Stickeler E; Rücker G; Buroh S; Asberger J; Dany N; Thornton S; Iborra S; Hirschfeld M; Gitsch G; Mayer S
Clin Breast Cancer; 2016 Aug; 16(4):e119-32. PubMed ID: 27067040
[TBL] [Abstract][Full Text] [Related]
35. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
[TBL] [Abstract][Full Text] [Related]
36. Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk for Screen-Detected and Interval Cancers: A Case-Control Study.
Kerlikowske K; Scott CG; Mahmoudzadeh AP; Ma L; Winham S; Jensen MR; Wu FF; Malkov S; Pankratz VS; Cummings SR; Shepherd JA; Brandt KR; Miglioretti DL; Vachon CM
Ann Intern Med; 2018 Jun; 168(11):757-765. PubMed ID: 29710124
[TBL] [Abstract][Full Text] [Related]
37. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
39. Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
Skarping I; Förnvik D; Zackrisson S; Borgquist S; Rydén L
Breast Cancer Res Treat; 2021 Aug; 189(1):131-144. PubMed ID: 34120224
[TBL] [Abstract][Full Text] [Related]
40. Mammographic density and breast cancer in women from high risk families.
Ramón Y Cajal T; Chirivella I; Miranda J; Teule A; Izquierdo Á; Balmaña J; Sánchez-Heras AB; Llort G; Fisas D; Lope V; Hernández-Agudo E; Juan-Fita MJ; Tena I; Robles L; Guillén-Ponce C; Pérez-Segura P; Luque-Molina MS; Hernando-Polo S; Salinas M; Brunet J; Salas-Trejo MD; Barnadas A; Pollán M
Breast Cancer Res; 2015 Jul; 17(1):93. PubMed ID: 26163143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
